(Q37793151)

23 August 2017

title

Differential gene expression and translational approaches to identify biomarkers of interferon beta activity in multiple sclerosis (English)

1 reference

23 August 2017

Differential Gene Expression and Translational Approaches to Identify Biomarkers of Interferon Beta Activity in Multiple Sclerosis (English)

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

21 July 2024

0 references

0 references

Ed Croze

1

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20874251

21 July 2024

publication date

1 October 2010

1 reference

full work available at URL

23 August 2017

http://www.liebertpub.com/doi/full-xml/10.1089/jir.2010.0022

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

http://www.liebertpub.com/doi/pdf/10.1089/jir.2010.0022

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Journal of Interferon and Cytokine Research

21 July 2024

published in

1 reference

23 August 2017

volume

30

1 reference

23 August 2017

issue

10

1 reference

23 August 2017

page(s)

743-749

1 reference

Treatment with metallothionein prevents demyelination and axonal damage and increases oligodendrocyte precursors and tissue repair during experimental autoimmune encephalomyelitis

23 August 2017

cites work

1 reference

3 January 2024

https://opencitations.net/index/api/v1/citations/10.1002/JNR.10615

Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity

1

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Immunopathogenesis of multiple sclerosis

21 July 2024

2

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Mechanisms of action of interferon-beta in multiple sclerosis

21 July 2024

3

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis

21 July 2024

4

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Transcription-based prediction of response to IFNbeta using supervised computational methods

21 July 2024

5

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Charting protein complexes, signaling pathways, and networks in the immune system

21 July 2024

6

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Application of a priori established gene sets to discover biologically important differential expression in microarray data

21 July 2024

7

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Interferon beta-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis

21 July 2024

9

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

A network-based analysis of systemic inflammation in humans

21 July 2024

11

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis

21 July 2024

12

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis

21 July 2024

13

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event

21 July 2024

14

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes

21 July 2024

17

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays

21 July 2024

18

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Interferon-beta mechanisms of action in multiple sclerosis

21 July 2024

19

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Genome-wide network analysis reveals the global properties of IFN-beta immediate transcriptional effects in humans

21 July 2024

20

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Interferon-beta directly influences monocyte infiltration into the central nervous system.

21 July 2024

21

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease.

21 July 2024

22

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Systemic IFN-beta treatment induces apoptosis of peripheral immune cells in MS patients

21 July 2024

23

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Monitoring of multiple sclerosis immunotherapy: from single candidates to biomarker networks.

21 July 2024

24

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice

21 July 2024

25

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Dynamics of immune cell trafficking in interferon-beta treated multiple sclerosis patients

21 July 2024

27

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers.

21 July 2024

28

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis

21 July 2024

29

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Systems biology and new technologies enable predictive and preventative medicine.

21 July 2024

30

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

COPASI--a COmplex PAthway SImulator

21 July 2024

31

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells

21 July 2024

32

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

21 July 2024

Multiple sclerosis

33

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis.

21 July 2024

35

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 July 2024

36

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene.

21 July 2024

37

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Genomic approaches for reconstructing gene networks

21 July 2024

38

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Biochemistry of Interferons and Their Actions

21 July 2024

39

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis

21 July 2024

40

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases

21 July 2024

41

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Beta interferon restricts the inflammatory potential of CD4+ cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells

21 July 2024

42

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

21 July 2024

43

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Decreased integrin gene expression in patients with MS responding to interferon-beta treatment

21 July 2024

44

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease.

21 July 2024

45

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Perivascular spaces and the two steps to neuroinflammation

21 July 2024

46

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB).

21 July 2024

47

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Therapeutic targeting of Janus kinases

21 July 2024

49

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Heterogeneous, longitudinally stable molecular signatures in response to interferon-beta

21 July 2024

50

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression.

21 July 2024

51

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Predicting responders to therapies for multiple sclerosis

21 July 2024

52

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Genomic and proteomic analysis of multiple sclerosis. Opinion

21 July 2024

53

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Formation of a uniquely stable type I interferon receptor complex by interferon beta is dependent upon particular interactions between interferon beta and its receptor and independent of tyrosine phosphorylation

21 July 2024

54

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Interrogating the transcriptome

21 July 2024

55

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNbeta-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNbeta-related adverse effects in multiple sclerosis

21 July 2024

56

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis

21 July 2024

57

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Down-regulation of survivin expression in T lymphocytes after interferon beta-1a treatment in patients with multiple sclerosis

21 July 2024

58

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

How cells respond to interferons

21 July 2024

59

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers.

21 July 2024

60

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis.

21 July 2024

61

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9

21 July 2024

62

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

21 July 2024

63

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

21 July 2024

64

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Changes of serum sICAM-1 and MMP-9 induced by rIFN -1b treatment in relapsing-remitting MS

21 July 2024

65

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis

21 July 2024

66

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

CCR7 expression on peripheral blood lymphocytes is up-regulated following treatment of multiple sclerosis with interferon-beta

21 July 2024

67

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients

21 July 2024

68

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach

21 July 2024

69

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes.

21 July 2024

70

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

RNA-Seq: a revolutionary tool for transcriptomics

21 July 2024

71

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS

21 July 2024

72

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?

21 July 2024

73

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Genomic effects of IFN-beta in multiple sclerosis patients

21 July 2024

74

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

The interferons: biological effects, mechanisms of action, and use in multiple sclerosis

21 July 2024

75

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

Clinical Pharmacokinetics of Interferons

21 July 2024

76

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0022

21 July 2024

Identifiers

1 reference

23 August 2017

1 reference